Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | SVP, Human Resources | February 05, 2013 | February 07, 2013 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VERTEX PHARMACEUTICALS INC / MA
Report date February 05, 2013 · Filed February 07, 2013
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,382 |
Reported balance
After 2013-02-05 transaction · row 1
1 source rowRow 1 · 2013-02-05 · Grant · Acquired 10,166 · Balance 25,382 F1: Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2017, subject to (i) acceleration of 50% of shares upon (a) receiving filing confirmation for an NDA for a combination regimen that includes both ivacaftor and a corrector compound or (b) receiving filing confirmation for an sNDA that would increase the number of patients with CF eligible for ivacaftor monotherapy, and (ii) acceleration of 50% of shares upon (a) the announcement of proof-of-concept data for a drug candidate other than an HCV, cystic fibrosis, influenza or JAK3 inhibition drug candidate or (b) reaching a specified net sales level over a twelve month period for our CF products. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.11 · Expires 2023-02-04 | Direct | 45,750 |
Reported balance
After 2013-02-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2013-02-05 · Grant · Acquired 45,750 · Balance 45,750 F2: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/2013. |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 1,965 |
Reported balance
Holding disclosure · report date 2013-02-05 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,965 |
Filing footnotes · ownership attribution and instrument terms
F1: Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2017, subject to (i) acceleration of 50% of shares upon (a) receiving filing confirmation for an NDA for a combination regimen that includes both ivacaftor and a corrector compound or (b) receiving filing confirmation for an sNDA that would increase the number of patients with CF eligible for ivacaftor monotherapy, and (ii) acceleration of 50% of shares upon (a) the announcement of proof-of-concept data for a drug candidate other than an HCV, cystic fibrosis, influenza or JAK3 inhibition drug candidate or (b) reaching a specified net sales level over a twelve month period for our CF products.
F2: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/2013.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 05, 2013 Filed Feb 7, 2013 22:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantEmployee Stock Option (right to buy) · Derivative | 45,750 | $0.00 Strike: $45.11 | $0.00 |
DisclosureSEC source: 0001209191-13-007127 · doc4.xml · derivative · entry 3 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,750 Underlying: Common Stock · 45,750 shares Expires 2023-02-04 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/2013. Read SEC document |
| February 05, 2013 Filed Feb 7, 2013 22:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 10,166 | $0.01 | $101.66 |
DisclosureSEC source: 0001209191-13-007127 · doc4.xml · nonDerivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,382 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2017, subject to (i) acceleration of 50% of shares upon (a) receiving filing confirmation for an NDA for a combination regimen that includes both ivacaftor and a corrector compound or (b) receiving filing confirmation for an sNDA that would increase the number of patients with CF eligible for ivacaftor monotherapy, and (ii) acceleration of 50% of shares upon (a) the announcement of proof-of-concept data for a drug candidate other than an HCV, cystic fibrosis, influenza or JAK3 inhibition drug candidate or (b) reaching a specified net sales level over a twelve month period for our CF products. Read SEC document |
| November 16, 2012 Filed Nov 19, 2012 21:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,033 | $41.28 | $83,922.24 |
DisclosureSEC source: 0001209191-12-053796 · doc4.xml · nonDerivative · entry 2 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,216 F1 · kind: Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan under Rule 10b5-1. F3 · price: Ms. Kelly-Croswell undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $41.28 (range $41.01 to $41.82). Read SEC document |
| November 15, 2012 Filed Nov 19, 2012 21:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 355 | $40.59 | $14,409.45 |
DisclosureSEC source: 0001209191-12-053796 · doc4.xml · nonDerivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,249 F1 · kind: Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $40.59 (range $40.34 to $41.23). F3 · price: Ms. Kelly-Croswell undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| September 19, 2012 Filed Sep 21, 2012 20:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,093 | $0.00 Strike: $33.00 | $0.00 |
DisclosureSEC source: 0001209191-12-046401 · doc4.xml · derivative · entry 6 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,907 Underlying: Common Stock · 3,093 shares Expires 2019-10-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| September 19, 2012 Filed Sep 21, 2012 20:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 954 | $0.00 Strike: $32.16 | $0.00 |
DisclosureSEC source: 0001209191-12-046401 · doc4.xml · derivative · entry 5 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 954 shares Expires 2018-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| September 19, 2012 Filed Sep 21, 2012 20:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,047 | $57.61 | $233,147.67 |
DisclosureSEC source: 0001209191-12-046401 · doc4.xml · nonDerivative · entry 3 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,249 F1 · kind: Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $57.61 (range $57.05 to $57.94). F3 · price: Ms. Kelly-Croswell undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| September 19, 2012 Filed Sep 21, 2012 20:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 3,093 | $33.00 | $102,069.00 |
DisclosureSEC source: 0001209191-12-046401 · doc4.xml · nonDerivative · entry 2 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,296 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 19, 2012 Filed Sep 21, 2012 20:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 954 | $32.16 | $30,680.64 |
DisclosureSEC source: 0001209191-12-046401 · doc4.xml · nonDerivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,203 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 16, 2012 Filed Aug 20, 2012 21:20 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 953 | $0.00 Strike: $32.16 | $0.00 |
DisclosureSEC source: 0001209191-12-042654 · doc4.xml · derivative · entry 4 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 954 Underlying: Common Stock · 953 shares Expires 2018-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| August 16, 2012 Filed Aug 20, 2012 21:20 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 953 | $55.00 | $52,415.00 |
DisclosureSEC source: 0001209191-12-042654 · doc4.xml · nonDerivative · entry 2 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,249 F1 · kind: Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan under Rule 10b5-1. Read SEC document |
| August 16, 2012 Filed Aug 20, 2012 21:20 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 953 | $32.16 | $30,648.48 |
DisclosureSEC source: 0001209191-12-042654 · doc4.xml · nonDerivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,202 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 25, 2012 Filed Jul 26, 2012 20:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantEmployee Stock Option (right to buy) · Derivative | 30,500 | $0.00 Strike: $48.74 | $0.00 |
DisclosureSEC source: 0001209191-12-039155 · doc4.xml · derivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,500 Underlying: Common Stock · 30,500 shares Expires 2022-07-24 F1 · derivative.exercise_date: The option vests in 16 quarterly installments beginning on 10/25/2012. Read SEC document |
| May 24, 2012 Filed May 29, 2012 20:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 5,106 | $63.38 | $323,618.28 |
DisclosureSEC source: 0001209191-12-031019 · doc4.xml · nonDerivative · entry 2 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,249 F1 · kind: Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan under Rule 10b5-1. F3 · price: Ms. Kelly-Croswell undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $63.38 (range $63.06 to $63.62). Read SEC document |
| May 24, 2012 Filed May 29, 2012 20:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 900 | $62.74 | $56,466.00 |
DisclosureSEC source: 0001209191-12-031019 · doc4.xml · nonDerivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,355 F1 · kind: Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $62.74 (range $62.25 to $62.99). F3 · price: Ms. Kelly-Croswell undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 15, 2012 Filed May 16, 2012 20:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 37 | $65.24 | $2,413.88 |
DisclosureSEC source: 0001209191-12-028594 · doc4.xml · nonDerivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,255 F1 · kind: Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan under Rule 10b5-1. Read SEC document |
| May 07, 2012 Filed May 9, 2012 20:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 3,813 | $0.00 Strike: $18.93 | $0.00 |
DisclosureSEC source: 0001209191-12-027015 · doc4.xml · derivative · entry 8 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,813 shares Expires 2018-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| May 07, 2012 Filed May 9, 2012 20:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 28,593 | $0.00 Strike: $32.16 | $0.00 |
DisclosureSEC source: 0001209191-12-027015 · doc4.xml · derivative · entry 7 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,907 Underlying: Common Stock · 28,593 shares Expires 2018-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2012 Filed May 9, 2012 20:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 14,297 | $57.50 | $822,077.50 |
DisclosureSEC source: 0001209191-12-027015 · doc4.xml · nonDerivative · entry 5 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,255 F1 · kind: Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan under Rule 10b5-1. Read SEC document |
| May 07, 2012 Filed May 9, 2012 20:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 7,187 | $52.13 | $374,658.31 |
DisclosureSEC source: 0001209191-12-027015 · doc4.xml · nonDerivative · entry 4 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,552 F1 · kind: Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan under Rule 10b5-1. Read SEC document |
| May 07, 2012 Filed May 9, 2012 20:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 16,242 | $55.00 | $893,310.00 |
DisclosureSEC source: 0001209191-12-027015 · doc4.xml · nonDerivative · entry 3 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,739 F1 · kind: Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan under Rule 10b5-1. Read SEC document |
| May 07, 2012 Filed May 9, 2012 20:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 3,813 | $32.16 | $122,626.08 |
DisclosureSEC source: 0001209191-12-027015 · doc4.xml · nonDerivative · entry 2 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,981 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2012 Filed May 9, 2012 20:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 28,593 | $32.16 | $919,550.88 |
DisclosureSEC source: 0001209191-12-027015 · doc4.xml · nonDerivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,168 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2012 Filed Feb 9, 2012 21:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 8,133 | $36.80 | $299,294.40 |
DisclosureSEC source: 0001209191-12-008686 · doc4.xml · nonDerivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,575 F1 · kind: Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $36.80 (range $36.50 to $37.25). F3 · price: Ms. Kelly-Croswell undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 02, 2012 Filed Feb 6, 2012 21:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 45,750 | $0.00 Strike: $37.86 | $0.00 |
DisclosureSEC source: 0001209191-12-007774 · doc4.xml · derivative · entry 3 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,750 Underlying: Common Stock · 45,750 shares Expires 2022-02-01 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/02/2012. Read SEC document |
| February 02, 2012 Filed Feb 6, 2012 21:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 10,166 | $0.01 | $101.66 |
DisclosureSEC source: 0001209191-12-007774 · doc4.xml · nonDerivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,708 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/2/2016, subject to (i) earlier acceleration of 50% of shares upon (A) reaching specified aggregate product and royalty sales levels or (B) completing enrollment of a pivotal trial in two distinct disease indications other than HCV and cystic fibrosis and (ii) earlier acceleration of 50% of shares upon receiving filing confirmation for an NDA for an all-oral regimen for the treatment of HCV infection. Read SEC document |
| January 19, 2012 Filed Jan 23, 2012 21:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 10,166 | $37.00 | $376,142.00 |
DisclosureSEC source: 0001209191-12-004850 · doc4.xml · nonDerivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,542 F1 · kind: Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $37.00 (range $36.84 to $37.15). F3 · price: Ms. Kelly-Croswell undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| September 08, 2011 Filed Sep 9, 2011 17:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 953 | $47.50 | $45,267.50 |
DisclosureSEC source: 0001209191-11-047231 · doc4.xml · nonDerivative · entry 2 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,708 F1 · kind: Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan under Rule 10b5-1. Read SEC document |
| September 08, 2011 Filed Sep 9, 2011 17:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 953 | $18.93 | $18,040.29 |
DisclosureSEC source: 0001209191-11-047231 · doc4.xml · nonDerivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,661 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2011 Filed Sep 1, 2011 18:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Options · Derivative | 953 | $0.00 Strike: $18.93 | $0.00 |
DisclosureSEC source: 0001209191-11-046264 · doc4.xml · derivative · entry 5 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 953 Underlying: Common Stock · 953 shares Expires 2018-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/07/2008, except that the first quarterly vesting occurred on May 15, 2008. Read SEC document |
| August 31, 2011 Filed Sep 1, 2011 18:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 800 | $46.17 | $36,936.00 |
DisclosureSEC source: 0001209191-11-046264 · doc4.xml · nonDerivative · entry 3 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,708 F1 · kind: Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan under Rule 10b5-1. F3 · price: Ms. Kelly-Croswell undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $46.17 (range $46.00 to $46.44). Read SEC document |
| August 31, 2011 Filed Sep 1, 2011 18:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,527 | $45.63 | $69,677.01 |
DisclosureSEC source: 0001209191-11-046264 · doc4.xml · nonDerivative · entry 2 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,508 F1 · kind: Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $45.63 (range $45.17 to $45.96). F3 · price: Ms. Kelly-Croswell undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| August 31, 2011 Filed Sep 1, 2011 18:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 953 | $18.93 | $18,040.29 |
DisclosureSEC source: 0001209191-11-046264 · doc4.xml · nonDerivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,035 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2011 Filed Sep 9, 2011 17:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Options · Derivative | 953 | $0.00 Strike: $18.93 | $0.00 |
DisclosureSEC source: 0001209191-11-047231 · doc4.xml · derivative · entry 4 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,813 Underlying: Common Stock · 953 shares Expires 2018-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/07/2008, except that the first quarterly vesting occurred on May 15, 2008. Read SEC document |
| July 29, 2011 Filed Aug 1, 2011 18:31 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 954 | $0.00 Strike: $28.84 | $0.00 |
DisclosureSEC source: 0001209191-11-041693 · doc4.xml · derivative · entry 4 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 954 shares Expires 2021-07-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| July 29, 2011 Filed Aug 1, 2011 18:31 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 954 | $52.50 | $50,085.00 |
DisclosureSEC source: 0001209191-11-041693 · doc4.xml · nonDerivative · entry 2 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,082 F1 · kind: Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan under Rule 10b5-1. Read SEC document |
| July 29, 2011 Filed Aug 1, 2011 18:31 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 954 | $28.84 | $27,513.36 |
DisclosureSEC source: 0001209191-11-041693 · doc4.xml · nonDerivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,036 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 13, 2011 Filed Jul 14, 2011 19:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 30,500 | $0.00 Strike: $51.75 | $0.00 |
DisclosureSEC source: 0001209191-11-039507 · doc4.xml · derivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,500 Underlying: Common Stock · 30,500 shares Expires 2021-07-12 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 07/13/2011. Read SEC document |
| July 12, 2011 Filed Jul 13, 2011 19:02 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 953 | $0.00 Strike: $28.84 | $0.00 |
DisclosureSEC source: 0001209191-11-039367 · doc4.xml · derivative · entry 4 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 954 Underlying: Common Stock · 953 shares Expires 2017-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan vesting in 16 quarterly installments from 07/12/2007. Read SEC document |
| July 12, 2011 Filed Jul 13, 2011 19:02 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 953 | $51.22 | $48,812.66 |
DisclosureSEC source: 0001209191-11-039367 · doc4.xml · nonDerivative · entry 2 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,082 F1 · kind: Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $51.22 (range $50.21 to $51.56). F3 · price: Ms. Kelly-Croswell undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| July 12, 2011 Filed Jul 13, 2011 19:02 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 953 | $28.84 | $27,484.52 |
DisclosureSEC source: 0001209191-11-039367 · doc4.xml · nonDerivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,035 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 25, 2011 Filed May 26, 2011 19:57 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,200 | $56.22 | $123,684.00 |
DisclosureSEC source: 0001209191-11-031210 · doc4.xml · nonDerivative · entry 2 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,082 F1 · kind: Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan under Rule 10b5-1. F3 · price: Ms. Kelly-Croswell undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $56.22 (range $56.04 to $56.57). Read SEC document |
| May 25, 2011 Filed May 26, 2011 19:57 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,960 | $55.49 | $108,760.40 |
DisclosureSEC source: 0001209191-11-031210 · doc4.xml · nonDerivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,212 F1 · kind: Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $55.49 (range $55.05 to $55.92). F3 · price: Ms. Kelly-Croswell undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 17, 2011 Filed May 18, 2011 17:47 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 224 | $57.38 | $12,853.12 |
DisclosureSEC source: 0001209191-11-029275 · doc4.xml · nonDerivative · entry 2 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,242 F1 · kind: Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan under Rule 10b5-1. F3 · price: Ms. Kelly-Croswell undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $57.38 (range $57.15 to $57.56). Read SEC document |
| May 17, 2011 Filed May 18, 2011 17:47 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 439 | $56.62 | $24,856.18 |
DisclosureSEC source: 0001209191-11-029275 · doc4.xml · nonDerivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,466 F1 · kind: Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $56.62 (range $56.33 to $56.99). F3 · price: Ms. Kelly-Croswell undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 09, 2011 Filed May 10, 2011 20:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 1,906 | $0.00 Strike: $18.93 | $0.00 |
DisclosureSEC source: 0001209191-11-027255 · doc4.xml · derivative · entry 6 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,719 Underlying: Common Stock · 1,906 shares Expires 2018-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan vesting in 16 quarterly installments from 02/07/2008. Read SEC document |
| May 09, 2011 Filed May 10, 2011 20:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,076 | $57.53 | $61,902.28 |
DisclosureSEC source: 0001209191-11-027255 · doc4.xml · nonDerivative · entry 4 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,242 F1 · kind: Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan under Rule 10b5-1. F3 · price: Ms. Kelly-Croswell undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $57.53 (range $57.13 to $57.90). Read SEC document |
| May 09, 2011 Filed May 10, 2011 20:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 530 | $56.69 | $30,045.70 |
DisclosureSEC source: 0001209191-11-027255 · doc4.xml · nonDerivative · entry 3 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,318 F1 · kind: Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan under Rule 10b5-1. F3 · price: Ms. Kelly-Croswell undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $56.69 (range $56.22 to $56.97). Read SEC document |
| May 09, 2011 Filed May 10, 2011 20:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $55.72 | $16,716.00 |
DisclosureSEC source: 0001209191-11-027255 · doc4.xml · nonDerivative · entry 2 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,848 F1 · kind: Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $55.72 (range $55.52 to $55.90). F3 · price: Ms. Kelly-Croswell undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 09, 2011 Filed May 10, 2011 20:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,906 | $18.93 | $36,080.58 |
DisclosureSEC source: 0001209191-11-027255 · doc4.xml · nonDerivative · entry 1 Kelly Lisa · CIK 0001349077 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,148 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.